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Introduction
Metastasis is the most poorly understood aspect of breast 
cancer, a disease that causes roughly half a million deaths 
each year worldwide and is the most common malig-
nancy in women in the United States [1]. Th  e ﬁ  eld of 
metastasis research is at least a century old [2], and 
classical views hold that the metastatic phenotype is 
possessed by clonal variants within a tumor that happen 
to acquire the requisite mutations [1,3]. Progress in meta-
stasis research, however, has stagnated because of a lack 
of eﬀ   ective tools to comprehensively understand the 
complex network of signaling pathways that drives the 
multistep process of the metastatic cascade [4,5]. Th  e 
advent of genomic proﬁ   ling technology has led to 
paradigm-shifting advances in the conceptual and 
mechanistic understanding of the metastatic process 
over the past decade. Th   e early waves of clinical micro-
array studies found that gene expression proﬁ  les  in 
primary tumors could discriminate breast cancer patients 
with good prognosis from those with poor prognosis [6]. 
Th   ese works suggested that metastatic propensity may be 
selected for in the entire tumor and can be accurately 
assessed using bioinformatic approaches. Th  us,  an 
ensuing debate centered on whether there are any 
metastasis-speciﬁ  c genes, and, if so, how they could be 
identiﬁ   ed [7,8]. Genomic proﬁ   ling of clinical tumor 
samples alone, however, is fundamentally limited in 
provid  ing functional insights, as it oﬀ  ers no method for 
testing hypotheses mechanistically. Th  ough prognos-
tically eﬀ   ective, such studies on their own have been 
unable to provide a satisfactory, functional understanding 
of the genetic and epigenetic underpinnings of metastatic 
progression.
In contrast, advances in animal models of metastasis 
have been applied to directly test the hypotheses 
generated by classical as well as modern genomic 
approaches to studying disease progression. Such studies 
have utilized the ability to create or isolate variants of 
breast cancer cell lines and quantitatively monitor their 
metastatic abilities in mice using various models of meta-
static progression. Th  ese studies have provided critical 
insights into the mechanistic basis of metastatic progres-
sion and have suggested updated conceptual frameworks 
that have helped reconcile the diﬀ  erences between prior 
models of metastasis [4,9]. Considered alone, however, 
animal models of breast cancer progression will always 
have questionable applicability to human disease.
Th   e combination of advances in bioinformatics 
approaches, animal model technology, and clinical 
dataset assembly has laid the groundwork for integrated 
studies to rapidly expand our knowledge of the breast 
cancer metastasis genetic program. While a mature 
understanding of this program has not yet been 
cemented, insights into the roles and functionality of 
metastasis-speciﬁ   c genes and pathways have recently 
emerged. Many studies have used powerful methodolo-
gies to deﬁ   ne a gene expression program - such as a 
signal transduction pathway or physiological response 
program - and test its ability to signiﬁ  cantly  aﬀ  ect 
metastatic progression in the experimental setting, as 
well as test whether it shows elevated activity in large, 
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nostication. In this review, our aim is not to exhaustively 
cover the understanding of any one such gene expression 
program in disease progression. Rather, we will instead 
focus our discussion on exemplary integrative studies 
that use functional genomics approaches to study the 
roles of various classical and novel signaling pathways in 
breast cancer metastasis.
Breast cancer subtypes - early portraits
Breast cancer has long been recognized as a hetero  gene-
ous disease that can be classiﬁ   ed using a variety of 
characteristics and markers, such as histological grade, 
estrogen receptor, progesterone receptor and HER2/
ERBB2  status, and p53 mutational status. Around the 
turn of the century, nascent cDNA microarray technology 
made possible the ﬁ  rst investigations into genome-wide 
expression patterns observed in breast cancer patients. 
Th  e  ﬁ  rst wave of such breast cancer proﬁ  ling studies per-
formed microarray analyses on primary breast cancer 
tumor samples from small to medium sized patient 
cohorts [10-13]. In these works, unsupervised hierar-
chical clustering methodology was used to group patients 
according to patterns of gene expression, and the diﬀ  er-
entiating clusters of genes were scrutinized for biological 
meaning. In Perou and colleagues’ landmark study [11], 
breast cancer patients were found to cluster into four 
discernable groups that, given immunohistochemical 
analyses and the identities of the diﬀ  erentiating genes, 
were annotated as basal-like, luminal-like, ERBB2+, and 
normal breast-like. Th  ese  classiﬁ   cations were later 
validated in an independent cohort and it was further 
shown that the basal-like group patients had signiﬁ  cantly 
worse prognoses than patients from other subgroups 
[12]. Notably, it was also observed here and in later work 
[14] that rare cases of matched primary tumors and 
metastatic lesions from the same patient always clustered 
together.
Th   ese initial works oﬀ  ered valuable insights into tumor 
biology and demonstrated that intrinsic gene expression 
patterns could be used in conjunction with histopatho-
logical characteristics for a far more sophisticated tumor 
classiﬁ  cation system. However, they oﬀ  ered little infor-
mation pertinent to the key question of what cohesive 
genetic programs underlie metastatic progression. In 
particular, the ﬁ  nding that matched primary and meta-
static tumor samples cluster together could be inter-
preted in two quite diﬀ  erent ways. One interpretation is 
that the genetic programs of primary tumors are fully 
maintained in metastatic lesions. An alternative expla  na-
tion is that primary and secondary tumors are only more 
similar to one another than to tissue from another 
individual, with signiﬁ  cant expression diﬀ  erences between 
primary and metastatic tumors still being possible.
Predicting metastasis using expression profi  les - 
prognosis signatures
Given the diﬃ   culty in predicting metastatic progression 
based on histopathological and clinical criteria, most 
breast cancer patients receive adjuvant therapy. However, 
had they been left untreated, most of these patients 
would not have suﬀ  ered from metastatic disease, render-
ing the therapy a cause of unnecessary suﬀ  ering  and 
expense. Recognizing the power of microarray approaches 
to discriminate breast cancer patients into clinically 
informative groups, several studies aimed at using clus-
ter  ing approaches to tackle the prognostication problem 
(Table 1). While methodologies varied, conclusions were 
similar: gene expression signatures can very eﬀ  ectively 
predict which patients survive and which succumb to 
metastatic disease, ostensibly supporting the view that 
metastatic propensity is selected for early in tumor 
progression.
Th  e  ﬁ   rst prognosis signature study [15] used a 
supervised clustering approach to determine which genes 
could most eﬀ   ectively discriminate patients between 
those with good or poor prognosis. Such analysis led to 
the identiﬁ  cation of a poor-prognosis signature consist-
ing of 70 genes, many of which coded for proteins in-
volved in processes such as cell cycle progression, 
invasion, and angiogenesis. Ultimately, the signature was 
able to correctly classify more than 80% of the patients as 
having good or poor prognosis, thus achieving a marked 
improvement in prognostication compared to standard 
methodologies. While this study used a relatively modest 
number of patient samples (n = 78), the eﬃ   cacy of the 
prognostic signature was validated in a larger (n = 295), 
partially overlapping set of clinical samples [16].
While this original 70-gene signature has had direct 
clinical impact (commercialized as the MammaPrint, 
made available to patients in the United States in 2007), it 
is by no means the only eﬀ  ective prognosis signature. 
Using diﬀ   erent patient cohorts, array platforms, and 
statistical methodologies, an alternative 76-gene signa-
ture was also reported [17], which provided comparably 
accurate prognostication to the 70-gene signature. 
However, while the 70- and 76-gene signatures consisted 
of similar classes and functional groups of genes [18], 
they had strikingly little actual overlap, with only three 
genes in common. Th   is suggests that the given identities 
of signature genes are not nearly as important as the 
biological process of which they are but one repre  sen-
tative. Cementing this point, it was shown that, using the 
same dataset and similar but non-identical methodology, 
many diﬀ   erent 70-gene poor prognosis signatures of 
equivalent accuracy can be derived out of the original 
data [19]. Furthermore, a diﬀ   erent type of approach 
compared expression data from primary tumors of 
various tissues to those of metastatic adenocarcinoma 
Blanco and Kang Breast Cancer Research 2011, 13:206 
http://breast-cancer-research.com/content/13/2/206
Page 2 of 9lesions and found a discriminating 128-gene metastasis 
signature. Th  is signature was furthermore shown to be 
active in a subset of primary tumors - with this subset 
having a signiﬁ  cantly poorer prognosis than the rest of 
the patients [20].
Th   ese studies revealed strong implications to the meta-
stasis genetic program debate. Speciﬁ  cally, they argued in 
diﬀ  erent ways that metastatic propensity must indeed be 
captured within the phenotypes under selection at the 
primary tumor stage, otherwise no such prognostication 
would be possible. However, this argument suﬀ  ers from 
conceptual diﬃ   culties - why would a metastatic pheno-
type be under selection in cells of the primary tumor? - 
and also contradicts the classic work of Fidler and others. 
Furthermore, the paucity of matched primary tumor and 
metastatic lesion pairs (n = 2 in [11] and n = 8 in [14]) 
renders these clinical studies unable to truly address the 
question of metastasis-speciﬁ   c genetic events. While 
these diﬃ   culties could perhaps be considered academic, 
an issue of more immediate concern is that the functional 
interchangeability and lack of overlap between these 
signatures has resulted in the proposal of few, if any, 
protein products as potential therapeutic targets for 
blocking metastatic progression. Functional - rather than 
purely bioinformatic - studies are therefore required to 
give further understanding to the metastasis genetic 
program.
Animal models of metastatic progression
To test whether there could be genes and signaling 
pathways whose activation speciﬁ  cally aﬀ  ects metastatic 
progression, experimental animal models of breast 
cancer progression have been utilized. Compared to 
clinical proﬁ   ling studies, animal models of metastasis 
have several critical advantages, which stem largely from 
the ability to isolate and characterize both primary 
tumors and distant metastatic lesions, and to manipulate 
the expression levels of one to several genes at a time to 
directly test their roles in disease progression. Such 
methodology has profoundly advanced the understanding 
of how, on a mechanistic level, the metastatic program is 
executed, and has also provided further insights into the 
complexity of metastatic disease.
Advancing Fidler’s classic work [1,21], several studies 
have used in vivo selection approaches to ultimately 
deter  mine which genes drive metastasis to which organs, 
with the breast-to-bone, -lung, and -brain tropisms each 
having been investigated to date (Table 1) [22-24]. Such 
investigations have involved experimental metastasis 
assay xenografts of weakly metastatic cells followed by 
isolation of secondary lesions in the tissue of interest. 
Microarray-based comparisons of the parental lines to 
aggressive, organ-tropic sublines have yielded the signa-
tures of genes under selection during the late stage meta-
static program of interest. Juxtaposing the breast-to-bone 
Table 1. Gene expression signature analysis of breast cancer
Study Signature  Size  (genes)  Type  Validation
van ‘t Veer et al. [15]  Poor prognosis  70  Classifi  er  Clinical
Wang et al. [17]  Poor prognosis  76  Classifi  er  Clinical
Ramaswamy et al. [20]  General metastasis  128  Classifi  er  Clinical
Chang et al. [34]  Wound healing  512  Physiological response  Clinical
Finak et al. [37]  Stromal  26  Classifi  er  Clinical
Troester et al. [38]  Stromal  155  Classifi  er  Clinical
Farmer et al. [39]  Stromal  50  Classifi  er, metagene  Clinical
Chi et al. [42]  Epithelial hypoxia  168  Physiological response  In vitro, clinical
Winter et al. [44]  Hypoxia  99  Classifi  er, metagene  Clinical
Buff  a et al. [41]  Hypoxia  51  Classifi  er, metagene  Clinical
Hu et al. [43]  VEGF  13  Classifi  er  Clinical
Kang et al. [23]  Bone metastasis  102  Tissue tropism  Animal
Minn et al. [24]  Lung metastasis  95  Tissue tropism  Animal, clinical
Bos et al. [22]  Brain metastasis  243  Tissue tropism  Animal, clinical
Bild et al. [50]  Myc, E2F3, Ras, Src, β-catenin  248, 298, 348, 73, 98  Signaling pathway  Clinical, in vitro
Nguyen et al. [52]  WNT in lung cancer  81  Signaling pathway  Animal, clinical
Padua et al. [55]  TGF-β [53]  153  Signaling pathway  Animal, clinical
Zhang et al. [54]  Src [50]  172  Signaling pathway  Animal, clinical
TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
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mative to the conceptual framework of metastasis. Firstly, 
the bone and lung metastasis programs are distinct. 
While the bone and lung metastasis signatures (BMS and 
LMS) contain 102 and 95 genes, respectively, only six 
genes are common to both. Secondly, bone metastasis 
genes appear to be particular to bone microenvironment 
functionality, whereas lung metastasis genes have less 
obvious roles in the lung microenvironment and appear 
instead to facilitate general aggressive growth and 
invasive  ness. BMS genes such as CXCR4, CTGF,  and 
IL-11 have been shown to play key roles in the ‘vicious 
cycle’ [25] of cancer cell-driven osteolysis [26-28], while 
LMS genes such as ID1, MMP1 and 2, and SPARC have 
been shown to promote the general phenotypes of 
growth, invasion, and adhesion, respectively [29-31]. Un-
sur  prisingly, then, the bone metastasis gene expression 
program has little overlap with the 70-gene poor prog-
nosis signature, while the LMS has signiﬁ  cant overlap 
with multiple poor prognosis signatures and can indeed 
be used for eﬀ  ective prognostication.
Th  e  organ-speciﬁ  c metastasis studies have also laid the 
groundwork for advanced, mechanistic studies to further 
dissect the processes of breast cancer progression. 
Studies have assessed, for example, the physiological role 
of the metalloproteinases MMP1 and ADAMTS1 in 
breast cancer bone metastasis and uncovered a role for 
epidermal growth factor receptor inhibitors in targeting 
the reactive stroma in osteolytic metastasis [32]. In lung 
metastasis, the combinatorial eﬀ  ects  of  COX2, EREG, 
and MMP1 and 2 were shown to promote primary tumor 
angiogenesis and extravasation of metastatic cells from 
the lung capillaries [33]. Here it was also found that 
pharmacological inhibition of these genes with targeting 
small molecule inhibitors ablated these phenotypes in 
aggressive lung metastasis breast cancer models.
Taken together, the results from these landmark clinical 
and experimental animal studies indicate that both sides 
of the metastasis genes debate are partially correct. On 
one hand, some degree of metastatic propensity is under 
selection at the primary tumor stage, as the prognos  ti-
cation studies would have failed were this not the case. 
On the other hand, some other components of the 
metastatic program must arise later, otherwise the animal 
studies would not have succeeded in ﬁ  nding such striking 
diﬀ   erences between primary and secondary, organ-
speciﬁ   c lesions. Th  us, it appears that, while there is 
indeed an early (primary tumor stage) metastatic pro-
gram under selection, it should appropriately be con-
sidered necessary but not suﬃ   cient for distant metastasis 
to occur. More importantly, the tumors of metastatic 
disease have an at least moderately diﬀ  erent  genetic 
makeup to those of the primary tumor, and eﬀ  ective 
treatments will likely need to target the factors critical to 
microenvironment-speciﬁ  c tumor survival. In short, the 
functional power of experimental models must be 
synergized with the relevance of clinical datasets to 
appropriately explore the genes and pathways that deﬁ  ne 
and undergird breast cancer metastatic progression.
Integrated studies to understand breast cancer 
metastasis signaling
Central to the advances in understanding of metastasis-
speciﬁ  c gene expression changes was the aforementioned 
recognition that, while the individual genes of various 
prognosis signatures may be interchangeable, the signal-
ing pathways they represent are consistent. Pathway-level 
analyses therefore have several advantages over both 
single gene and gene expression proﬁ  le studies. Com-
pared to single gene studies, they can take advantage of 
the statistical power of gene sets, in which the activity 
readout is not dependent on the expression of any single 
gene but, rather, is determined by the concerted enrich-
ment of the group overall. And in comparison to proﬁ  les, 
they test the activity of genes involved in a biologically 
deﬁ  ned (and therefore experimentally testable) pheno-
typic process.
Several studies have looked at signal transduction path-
ways or sets of genes of similar function as the unit of 
analysis to study metastatic progression and prognosti-
cation (Table 1). One approach started with the long 
standing observation that the physiology of the tumor-
stroma interface appears to have much in common with 
that of a wound that is in the healing process, given the 
potent proliferative, invasive, and angiogenic stimulations 
in both contexts. Using a 512-gene ‘core serum response’ 
(CSR) signature as representative of the wound healing 
gene expression program, Chang et al. [34] found that 
CSR-active patients had signiﬁ   cantly worse prognoses 
than CSR-inactive patients and were largely characterized 
as belonging to the ‘basal-like’ breast cancer subtype. 
Furthermore, several CSR genes and proteins involved in 
cell-cell communication (ESDN and SDR1) and extra-
cellular matrix remodeling (LOXL2, PLOD2, and PLAUR) 
were shown to be upregulated in invasive ductal carci-
noma samples by tissue microarray analysis. Th  us, the 
CSR can be ﬁ   rstly considered a distinct prognosis 
classiﬁ  er with similar power to previous signatures. How-
ever, in being deﬁ  ned by a speciﬁ  c physiological process 
(rather than general good versus poor prognosis), it is far 
more biologically coherent than previous signatures. In 
particular, such work has given rise to the concept of the 
‘reactive stroma’ [35] as a crucial component in meta-
static progression. As metastasis is deﬁ  ned by invasion 
into foreign tissue, stromal components such as cancer-
associated ﬁ   broblasts have been shown to undergo 
inﬂ   ammatory-like responses that help mediate tumor 
progression [36]. Furthermore, gene expression proﬁ  les 
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successively classify and prognosticate patients into 
appro  priate subgroups and outcomes [37,38]. Interest-
ingly, stromal signatures can not only distinguish good 
from poor prognosis, but also have been shown to predict 
response of breast cancer patients to chemotherapeutic 
treatment [39].
Other physiological responses have been used as the 
basis for hypothesis-driven investigations into pathways 
that could be promoting metastatic progression. Th  e 
hypoxia response is one such physiological program that 
is thought to enable metastatic invasion into the circu-
latory system. Under conditions of low oxygen (hypoxia), 
which are common in large tumors, the hypoxia-
inducible factor-1α transcription factor subunit is 
stabilized and activates a pro-angiogenic gene expression 
program that results in enhancement of local vasculari-
zation. Th   e angiogenic response is thought to play a dual 
role in tumor progression. While ﬁ   rst functioning to 
supply the growing (and starving) tumor with oxygen and 
other essential nutrients, angiogenesis also aids in tumor 
meta  stasis by providing entryways for primary tumor 
cells into the circulatory system [40]. Analyses in both 
breast and head and neck cancer [41-44] have described 
hypoxic responses and used them to prognosticate 
patient groups across a variety of cancer types. Response 
signature derivation methods varied considerably, as did 
signature size and gene identity (Table 1). While one 
approach used in vitro hypoxia-induced genes for 
signature building [42], others started with small sets of 
known hypoxia-response genes and built metagene 
networks oﬀ   of them for prognostication eﬀ  orts [41,44]. 
Despite methodology diﬀ   erences, all approaches had 
high rates of success in patient prognostication in various 
cancers. Interestingly, a vascular endothelial growth 
factor-based signature was found to be especially active 
in distant metastases compared to primary tumors or 
their local metastases, supporting the hypothesis that 
primary tumors and distant meta  stases do harbor 
signiﬁ   cant gene expression diﬀ   erences despite overall 
clustering-based similarities [43]. Experi  mental analyses 
have further investigated the role of the hypoxic response 
in animal models of organ-speciﬁ   c breast cancer 
metastasis, ﬁ  nding that while bone and lung metastases 
utilize diﬀ   erent hypoxic gene response programs and 
have diﬀ  erent dependence on angiogenic response, both 
pathological conditions are highly respon  sive to hypoxia 
inhibitor treatments [45].
Although pathway-based analyses highlight the func-
tional eﬀ  ects of concerted gene expression changes, they 
typically shed little light on one of the key questions in 
metastatic progression, which is how to ﬁ  nd the under-
lying genetic mutations that drive these large-scale 
expres  sion program changes. However, by treating 
functional or pathway-based expression proﬁ   les as a 
pheno  type that can be used for linkage analyses, method-
ology has been developed to ﬁ   nd driver mutations in 
metastatic progression. Focusing on the CSR signature, a 
genomic method termed ‘SLAMS’ (stepwise linkage 
analysis of microarray signatures) was designed to ﬁ  nd 
candidate master regulators within cytogenetic abnor-
mali  ties linked to CSR activity [46]. A large region of 
genomic ampliﬁ  cation on chromosome 8q was found to 
be most strongly linked to activation of the CSR proﬁ  le, 
and mechanistic work indicated that overexpression of 
resident 8q genes Myc and COP9 was suﬃ   cient  to 
activate the CSR signature.
Such approaches have begun to bridge the gap between 
prognosis signatures and the underlying, driver muta-
tions that activate them. While the Myc  oncogene has 
long been known to be crucial for tumor progression 
[47], its role in promoting metastatic progression has 
remained unclear. Th  e SLAMS approach highlighted 
Myc in a novel context as the potential activator of a 
metastasis signaling program, but the actual functional 
contribution of Myc transcriptional activity to tumor 
progression was not investigated. However, later work 
has directly tested the role of Myc signaling in metastatic 
progression using a variety of model systems. Building oﬀ   
of the SLAMS approach, Wolfer et al. [48] searched for 
potential regulators of multiple poor prognosis signatures 
using the MCF7 breast cancer cell line as a testing 
platform. Th  rough a variety of informatics approaches, 
Myc activity was predicted and then validated to activate 
many (10 to 40%) of the genes in all of the poor prognosis 
signatures that were tested. Crucially, this cell line-based 
work was validated in vivo by demonstrating that stable 
knockdown of Myc in late stage MDA-MB-231 cells led 
to a dramatic reduction in lung metastasis burden with  out 
signiﬁ  cantly aﬀ  ecting the growth of the primary tumor.
While work based on cell lines and xenograft mouse 
metastasis models has advantages in terms of tractability 
and eﬃ     ciency, transgenic mouse models are often 
considered more biologically relevant. To study Myc-
based proﬁ  le induction and breast cancer progression, 
tumor subtypes were investigated in a mouse mammary 
tumor virus (MMTV)-Myc model of tumorigenesis [49]. 
Here it was observed that the MMTV-Myc transgene 
induced a striking variety of histological subtypes, with 
the ‘epithelial to mesenchymal transition/squamous’ type 
predicted to have poor prognosis by an independently 
derived metastasis signature. Accordingly, mice with 
tumors of this subtype indeed had far greater incidences 
of lung metastases than those of other subtypes. 
Furthermore, the epithelial to mesenchymal transition/
squamous signature was found to be elevated in ‘triple 
negative’ (estrogen receptor, progesterone receptor, and 
Her2 negative) poor prognosis patients in a clinical 
Blanco and Kang Breast Cancer Research 2011, 13:206 
http://breast-cancer-research.com/content/13/2/206
Page 5 of 9analysis, thus providing more evidence for Myc 
oncogene-based signaling in promoting metastatic 
progression.
Th  e importance of the Myc pathway in metastatic 
progression underscores the concept that some degree of 
the metastatic signaling program could be driven by 
classic oncogenes or other well-known signaling cascades 
that can adapt to promote metastasis-speciﬁ  c  gene 
expres  sion changes. To aid in pathway-based analyses, 
key signatures have been derived for assessing the path-
way activity of Src, H-Ras, E2F3, Myc, β-catenin [50], 
TCF/Wnt [51,52], and transforming growth factor 
(TGF)-β [53] by activating the pathway chemically or 
genetically and performing microarray proﬁ  ling experi-
ments. A key method for utilizing the power of these 
signatures has involved interrogating the activity of such 
pathways in clinical breast cancer datasets stratiﬁ  ed by a 
phenotype of interest and then testing the eﬀ  ects  of 
pathway activation on the relevant metastatic phenotype 
in the appropriate in vivo breast cancer progression 
model. In this fashion, powerful studies found that Src 
signaling mediates long-term survival (latency) and 
eventual outgrowth of clinical and experimental bone 
metastasis [54], whereas TGF-β activity promotes meta-
static dissemination to the lung, rather than bone tissue 
[55]. Furthermore, the intersection of the TGF-β and 
lung metastasis signatures was eﬀ  ectively used to narrow 
the list of candidate dissemination mediators and eﬀ  ect-
ively identify ANGPTL4 as a novel, TGF-β-responsive 
lung metastasis gene. Pathway activity studies have been 
undertaken in other cancer types, with implications for 
breast cancer resulting from included analyses. For 
example, eﬀ  orts to uncover signaling activity governing 
metastasis from lung carcinomas found that a lung WNT 
signaling program was functional in promoting meta-
stasis from lung cancer lines and prognostic of lung 
cancer patients in clinical databases [52]. Notably, bio-
informatic analyses indicated that the lung WNT signal-
ing program was not successful in prognosticating breast 
cancer. By extension, then, WNT signaling may be 
considered of lesser importance in breast cancer progres-
sion, thus narrowing the focus of breast cancer metastasis 
to aforementioned candidate pathways such as Src and 
TGF-β.
Novel pathways in metastasis
Clearly, well-known signaling pathways, such as the Myc, 
TGF-β, and Src pathways, are driving some components 
of breast cancer metastasis progression. However, given 
the complexity of the metastatic program, it would not be 
surprising to ﬁ   nd novel master regulators or key 
mediators of metastatic progression. One study used a 
hypothesis-driven approach to investigate the role of 
SATB1, a so-called ‘genome organizer’ that localizes to 
heterochromatin and recruits chromatin-remodeling 
enzymes and transcription factors to induce large scale 
transcriptional changes [56]. Cell line and large tissue 
array analyses found SATB1 to be strongly correlated to 
poor prognosis. In vivo analyses showed that SATB1 was 
both necessary and suﬃ     cient to promote both lung 
metastasis and primary tumor progression. Microarray 
analysis of SATB1 signaling indicated remarkably pene-
trant gene expression changes, with signiﬁ  cant regulation 
of multiple pertinent signatures, such as the 70-gene 
poor prognosis signature, and both the BMS and LMS. 
Curiously, despite the striking results, SATB1 signaling 
has not been linked to a known signal transduction 
pathway, and has also been shown to not promote the 
initially reported phenotypes [57]. Conceptually, its role 
as a general ‘genome organizer’ is diﬃ   cult to reconcile 
with the induction of such phenotypically speciﬁ  c and 
potent gene expression changes. Th   us, SATB1 presents a 
challenge to understanding metastasis signaling and 
suggests that large scale epigenetic regulators may play 
an important, yet underappreciated, role in tumor 
progression. Future studies will be required to explain the 
mystery.
Another recent analysis, much like the SLAMS 
approach, started with the motivating concept that muta-
tions driving metastatic progression should be identi-
ﬁ  able by their residence in areas of conserved cytogenetic 
abnormalities in poor prognosis tumor specimens. Using 
a computational approach termed ‘ACE’ (analysis of copy 
number abnormalities by expression data), Hu et al. [58] 
bypassed direct assessments of cytogenetic abnormalities 
and inferred them via interrogating clinical microarray 
expression data of genes according to chromosomal loca-
tion. Combining the clinical expression datasets from 
three previous studies [15-17], the ACE approach 
identiﬁ   ed a conserved window of ampliﬁ  cation  on 
chromo  some 8q22 in poor prognosis breast cancer 
patients. A combination of in vitro and in vivo analyses 
led to the hypothesis that the gene Metadherin (MTDH) 
was the functional target of this ampliﬁ  cation, and in vivo 
xenograft experiments strongly supported this view. 
Interestingly, further informatics analyses using the 
NCI-60 database indicated that MTDH was also strongly 
associated with chemoresistance. Th   is second phenotype 
was experimentally validated, highlighting MTDH as an 
example of a rare class of dual-functional genes that are 
active in two aspects of cancer progression. While 
MTDH was shown to aﬀ  ect the expression of many genes 
of relevance to the metastatic and chemoresistance 
phenotypes, the key signaling pathways upstream and 
downstream of MTDH remained elusive. Several other 
studies have recently explored MTDH signaling, with the 
NF-κB, phosphoinositide 3-kinase-AKT, Ha-Ras, FOXO3a, 
and Myc pathways [59-62] all having been suggested as 
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ality. Th   us, MTDH represents another novel mediator of 
malignant breast cancer progression with exciting, yet 
inconclusive, eﬀ  ects on breast cancer signaling.
Conclusion
Clinical proﬁ  ling studies, experimental models of disease 
progression, and especially the combination of both have 
greatly advanced the understanding of breast cancer 
metastasis since the turn of the century. However, despite 
the highlighted advances, metastasis remains a poorly 
understood biological process. Multiple genes and signal-
ing pathways have been shown to have the ability to 
inﬂ   uence metastatic progression, but few universal 
signaling events have been established as truly essential 
to the metastatic program. Confounding issues - clinical, 
experimental, and technical - continue to pose problems 
for a ﬁ   rm understanding of the underlying biology. 
Clinical datasets, for example, very rarely contain expres-
sion data from metastatic lesions that can be matched to 
their corresponding primary tumors. And experimental 
studies, of course, always come with extensive assump-
tions that can never truly be shown to be valid. Examples 
include the assumptions that the eﬀ  ect of the immune 
system (for xenograft studies), the eﬀ   ect of genetic 
diversity in the host, and the diﬀ  erences between mice 
and humans are small if not negligible. Furthermore, 
technical challenges range from trivial to dramatic. With 
microarray platforms continuing to evolve, signatures 
from older studies are becoming more diﬃ   cult  to 
interpret in light of newer studies with more probes and 
diﬀ   erent chemistries. Additionally, tumor specimens 
(unless obtained via laser capture microdissection) are 
typically in fact a mixture of tumor cells and stromal 
cells, making it diﬃ   cult to determine whether a gene of 
interest is being expressed by the tumor, stroma, or both.
Th   ese challenges notwithstanding, the metastasis ﬁ  eld 
is progressing rapidly and will continue to do so if it can 
take advantage of new methodologies, technologies, and 
conceptual ingenuities. Notably, the unabated ‘omics’ 
revolution is now oﬀ   ering avenues for several new 
approaches in metastasis prognostication and mechanis  tic 
hypothesis building. For example, several groups are 
utilizing next generation sequencing technology for 
whole-genome sequencing of primary tumors and 
matched metastases [63,64]. Such analyses will surely 
advance the ability to identify metastasis-speciﬁ  c driver 
mutations so long as the ‘data overload’ problem does not 
cripple the analyses. Additionally, proteomics-based 
approaches are advancing at a rapid pace as mass 
spectrometry technologies continue to evolve. While 
current sensitivity levels may make whole-cell proteomics 
approaches cumbersome, subcellular fractions are now 
being sequenced at the protein level with success [65,66]. 
Appropriate utilization of omics-level DNA-, RNA-, and 
protein-based approaches can only be expected to 
synergize in unraveling the mystery of the breast cancer 
metastasis genetic program.
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